Tesamorelin mastery course
Unit 5 of 11

HIV-associated lipodystrophy

Tesamorelin has a narrow but real home: HIV-associated lipodystrophy, a disfiguring fat-redistribution syndrome that le…

The one condition tesamorelin was built for, and why

Tesamorelin has a narrow but real home: HIV-associated lipodystrophy, a disfiguring fat-redistribution syndrome that left patients with excess visceral fat, dyslipidemia, and insulin resistance, with no approved drug to treat it.

This unit covers what lipodystrophy is, the pathobiology behind it, why tesamorelin rather than recombinant GH answered the need, which fat depot it targets, and how the modern integrase-inhibitor era has reshaped the population.

Key terms

What lipodystrophy looks like


What drives it


Why tesamorelin, not recombinant GH


The depot it moves


The population is changing